Advanced Medical Solutions Group plc

AIM:AMS Stock Report

Market Cap: UK£434.4m

Advanced Medical Solutions Group Valuation

Is AMS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AMS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AMS (£1.99) is trading above our estimate of fair value (£1.35)

Significantly Below Fair Value: AMS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMS?

Key metric: As AMS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AMS. This is calculated by dividing AMS's market cap by their current earnings.
What is AMS's PE Ratio?
PE Ratio39x
EarningsUK£11.13m
Market CapUK£434.40m

Price to Earnings Ratio vs Peers

How does AMS's PE Ratio compare to its peers?

The above table shows the PE ratio for AMS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35x
TSTL Tristel
30.9x17.5%UK£200.3m
CTEC ConvaTec Group
37.1x20.2%UK£4.5b
CNSL Cambridge Nutritional Sciences
39xn/aUK£6.8m
RUA RUA Life Sciences
33.1x61.7%UK£6.8m
AMS Advanced Medical Solutions Group
39x20.5%UK£434.4m

Price-To-Earnings vs Peers: AMS is expensive based on its Price-To-Earnings Ratio (39x) compared to the peer average (35x).

Price to Earnings Ratio vs Industry

How does AMS's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AMS 39.0xIndustry Avg. 30.2xNo. of Companies10PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AMS is expensive based on its Price-To-Earnings Ratio (39x) compared to the European Medical Equipment industry average (30.2x).

Price to Earnings Ratio vs Fair Ratio

What is AMS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39x
Fair PE Ratio30.3x

Price-To-Earnings vs Fair Ratio: AMS is expensive based on its Price-To-Earnings Ratio (39x) compared to the estimated Fair Price-To-Earnings Ratio (30.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AMS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£1.99
UK£2.63
+32.0%
12.2%UK£3.25UK£2.15n/a8
Dec ’25UK£2.13
UK£2.63
+23.6%
12.2%UK£3.25UK£2.15n/a8
Nov ’25UK£2.33
UK£2.63
+13.0%
12.2%UK£3.25UK£2.15n/a8
Oct ’25UK£2.15
UK£2.65
+23.2%
11.6%UK£3.25UK£2.15n/a9
Sep ’25UK£2.50
UK£2.58
+3.2%
13.6%UK£3.25UK£2.15n/a9
Aug ’25UK£2.44
UK£2.58
+5.8%
13.6%UK£3.25UK£2.15n/a9
Jul ’25UK£2.12
UK£2.58
+21.8%
13.6%UK£3.25UK£2.15n/a9
Jun ’25UK£2.17
UK£2.58
+18.9%
13.0%UK£3.25UK£2.15n/a10
May ’25UK£1.94
UK£2.52
+29.9%
14.2%UK£3.25UK£2.15n/a9
Apr ’25UK£1.96
UK£2.53
+29.2%
14.4%UK£3.25UK£2.10n/a10
Mar ’25UK£2.08
UK£2.55
+23.0%
18.6%UK£3.75UK£2.10n/a10
Feb ’25UK£2.11
UK£2.55
+21.3%
18.6%UK£3.75UK£2.10n/a10
Jan ’25UK£2.08
UK£2.52
+21.6%
19.1%UK£3.75UK£2.10n/a10
Dec ’24UK£2.04
UK£2.52
+23.7%
19.1%UK£3.75UK£2.10UK£2.1310
Nov ’24UK£2.07
UK£2.52
+21.9%
19.1%UK£3.75UK£2.10UK£2.3310
Oct ’24UK£2.01
UK£2.53
+25.9%
18.8%UK£3.75UK£2.10UK£2.1510
Sep ’24UK£2.50
UK£3.05
+22.1%
11.2%UK£3.85UK£2.67UK£2.5010
Aug ’24UK£2.48
UK£3.05
+23.1%
11.2%UK£3.85UK£2.67UK£2.4410
Jul ’24UK£2.26
UK£3.08
+36.3%
10.3%UK£3.85UK£2.70UK£2.1210
Jun ’24UK£2.27
UK£3.09
+36.2%
10.1%UK£3.85UK£2.75UK£2.1710
May ’24UK£2.45
UK£3.11
+27.0%
10.2%UK£3.85UK£2.75UK£1.949
Apr ’24UK£2.23
UK£3.08
+38.2%
10.5%UK£3.85UK£2.75UK£1.9610
Mar ’24UK£2.65
UK£3.12
+17.7%
10.6%UK£3.85UK£2.75UK£2.0810
Feb ’24UK£2.53
UK£3.09
+22.1%
10.9%UK£3.85UK£2.75UK£2.119
Jan ’24UK£2.59
UK£3.09
+19.2%
11.6%UK£3.85UK£2.75UK£2.088
Dec ’23UK£2.72
UK£3.09
+13.5%
11.6%UK£3.85UK£2.75UK£2.048

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 19:52
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Advanced Medical Solutions Group plc is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Julie SimmondsCanaccord Genuity
Keith RedpathCavendish